Halime K.
- Country
- Germany
- Department
- Innere Klinik (Tumorforschung)
Research Overview
- Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Patients With Previously Treated TROP2-Positive Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 2 Open‑Label Multicohort Study of Rinatabart Sesutecan Monotherapy in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer
- Neoadjuvant Evaluation of Darovasertib in Patients with Localized Uveal Melanoma
Data & Insights
Has run more than one trial at 81 of 236 partner sites.
Specializations
Ocular Oncology
This investigator specializes in treating uveal melanoma, focusing on innovative therapeutic approaches for both primary and metastatic cases. Their research encompasses neoadjuvant treatments for tumors in the eye wall and targeted therapies for HLA-A2 negative presentations.
- Primary uveal melanoma management
- Advanced metastatic eye cancer treatments
- Pre-surgical tumor reduction strategies
Their work extends to investigating novel combination therapies using targeted agents like darovasertib and crizotinib.
Precision Oncology
The investigator conducts research in biomarker-driven cancer treatments, particularly focusing on PIWIL1-positive advanced cancers. Their expertise includes developing personalized therapeutic approaches and evaluating novel targeted agents.
- Biomarker-specific cancer therapies
- Advanced cancer treatment optimization
- Combination therapy development
Their research involves evaluating innovative immunotherapy approaches and targeted treatment combinations.
Thoracic Oncology
The investigator studies advanced therapeutic options for non-small cell lung cancer, with particular emphasis on post-immunotherapy treatment strategies. Their work includes evaluation of therapeutic cancer vaccines and comparison with conventional chemotherapy approaches.
- Immunotherapy resistance management
- Novel vaccine therapeutics
- Advanced NSCLC treatment
Their research focuses on developing alternative treatment pathways for patients who have progressed after initial immunotherapy.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.